Lumos Pharma Inc

Lumos Pharma — NewLink Genetics — Q3 2018 Earnings Presentation

10 slides from Lumos Pharma's earnings presentation, Nov 1, 2018

  1. Slide 1: Third Quarter 2018 Financial Results

    Third Quarter 2018 Financial Results NewLink Genetics Corporation Nasdaq: NLNK November 1, 2018

  2. Slide 2: Introduction

    Introduction •Lisa Miller, Director of Investor Relations Clinical Priorities • Charles J. Link, Jr, MD, Chairman, CEO & CSO Clinical Updates and Guidance on Timing of Data •Eugene Kennedy, MD, Chief Medical Officer Third Quarter 2018 Financial Results • Carl Langren, Chief Financial Officer 2

  3. Slide 3: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements of NewLink Genetics that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward- looking statements,

  4. Slide 4: Indoximod Clinical Programs

    Indoximod Clinical Programs Front-line diffuse intrinsic pontine glioma (DIPG) Indoximod plus radiotherapy for pediatric patients with DIPG Early data show all patients demonstrated initial symptomatic improvement on therapy Phase 1b trial ongoing with updated data anticipated 2019 Recurrent maligna

  5. Slide 5: Indoximod plus Chemotherapy in Acute Myeloid Leukemia (AML)

    Indoximod plus Chemotherapy in Acute Myeloid Leukemia (AML) Phase 1b Exploring Minimal Residual Disease as a Surrogate Endpoint Combination with current Data to be presented by Emadi, et al at standard of care (7+3) ASH, December 2018 chemotherapy • Indoximod was well tolerated and does not appear t

  6. Slide 6: Abstracts Accepted for Upcoming Medical Meetings

    Abstracts Accepted for Upcoming Medical Meetings Abstract accepted for oral presentation at the ASH Annual Meeting, December 1-4, 2018 • Indoximod combined with standard induction chemotherapy is well tolerated and induces a high rate of complete remission with MRD-negativity in patients with newly

  7. Slide 7: Other Opportunities

    Other Opportunities Clinical Programs Under Evaluation . NLG207 (formerly CRLX101) – Nanoparticle formulation of the topoisomerase 1 inhibitor camptothecin – Acquired from Cerulean Pharma – Phase 2 trial to evaluate NLG207 plus weekly paclitaxel in recurrent ovarian cancer – Trial conducted in conju

  8. Slide 8: Financial Position

    Financial Position Q3 2018 End Cash and Equivalents $122.1 Million Average Quarterly Cash Use Projected ~$10 Million Cash Runway Projected Into 2H 2021 Shares Outstanding as of September 30, 2018 37.2 Million 8

  9. Slide 9: NewLink Genetics: Key Takeaways

    NewLink Genetics: Key Takeaways Clinical development plan targeting the most promising programs • Recurrent pediatric brain tumors, front-line DIPG, front-line AML, NLG802, NLG207 Strong cash position • Cash on hand at Q3 end $122.1 million • Estimated cash runway into the second half of 2021 exclud

  10. Slide 10: Q & A

    Q & A 10

NewLink Genetics — Q3 2018 Earnings Presentation on 6ix